Comparing the current results to its competitors, Amicus Therapeutics Inc reported Revenue increase in the 4 quarter 2025 by 23.72 % year on year. The sales growth was above Amicus Therapeutics Inc 's competitors' average revenue growth of 6.21 %, achieved in the same quarter.
Amicus Therapeutics Inc 's Comment on Competition and Industry Peers
The company faces competition from commercial enterprises, academic institutions, government agencies, and private and public research institutions. Competitors may possess greater financial resources and expertise in research and development, regulatory approvals, marketing, recruitment and retention of qualified personnel, and acquisition of complementary technologies. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger companies. The company's commercial opportunities may be diminished or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, or are less expensive.
Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Morphic Holding Inc's business model revolves around the development and commercialization of novel integrin therapeutics. They utilize a platform that combines structural biology, medicinal chemistry, and computational biology to design and develop small-molecule drugs. By strategically targeting and inhibiting integrin receptors, Morphic aims to address various diseases while offering potential benefits to patients.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Kamada Ltd is a biopharmaceutical company that operates on a business model centered around developing and commercializing specialty plasma-derived therapeutics. The company focuses on leveraging its expertise in proprietary protein purification technology and plasma collection to produce and deliver high-quality therapeutic products. Kamada aims to address unmet medical needs in various therapeutic areas, providing innovative treatment options to patients worldwide.
Sources:
Amicus Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Amicus Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
